Mesoblast Limited
MESO Healthcare Biotechnology
Mesoblast Limited’s revenue for fiscal 2026 (year ended June 2026) was $120.3 million, up 599.2% from fiscal 2025. Insiders bought in the last twelve months.
Follow MESO
Mesoblast Limited (MESO) EV/Sales
As of 16 October 2026, Mesoblast Limited (MESO) trades at a EV/Sales of 137×. Over the past ten years it has ranged from 0.0× (March 2016) to 258× (July 2017); the current reading is higher than 83% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 140× | 13.07% |
| FY2025 | 124× | 64.08% |
| FY2024 | 75.4× | (12.41%) |
| FY2023 | 86.1× | 171.01% |
| FY2022 | 31.8× | (72.55%) |
| FY2021 | 116× | 219.36% |
| FY2020 | 36.2× | 14.25% |
| FY2019 | 31.7× | (6.03%) |
| FY2018 | 33.7× | (86.18%) |
| FY2017 | 244× | 4,970.38% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 86.1× | 23.80% |
| Mar 2023 | 69.5× | 16.83% |
| Dec 2022 | 59.5× | 30.90% |
| Sep 2022 | 45.5× | 43.15% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| VIR Vir Biotechnology, Inc. compare | 3.7× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| URGN Urogen Pharma compare | 9.7× |
| SEPN Septerna, Inc. compare | 12.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| ZYME Zymeworks Inc. compare | 42.0× |
| MESO Mesoblast Limited | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)